Additional file 7: of LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients

Figure S3. Stemness properties of LGR5+ 8591 cells in vivo. (a) Xenografts produced by LGR5+ and LGR5− 8591 cells. (b) The subcutaneous xenografts growth rate generated by LGR5+ and LGR5− 8591 cells in BALB/c-nu mice (two-way ANOVA, P = 0.001). Data are shown as the mean ± SD (LGR5+ 8591: n = 5, LGR5− 8591: n = 5). (c) IHC staining of LGR5, Ki67, N-cadherin, SOX2and CD44 expression in LGR5+ xenografts and LGR5− xenografts (magnification × 200). (d) The percentage of positive expression of LGR5, Ki67, N-cadherin, SOX2and CD44 in LGR5+ xenografts and LGR5− xenografts (n = 5, Student t test). Error bars represent the mean ± SD. (e) The correlation between the levels of LGR5 and Ki67 by Spearman correlation analysis (P < 0.05, r = 0.7505, n = 10). (f) The correlation between the levels of LGR5 and N-cadherin by Spearman correlation analysis (P < 0.001, r = 0.8989, n = 10). (g) The correlation between the levels of LGR5 and SOX2 by Spearman correlation analysis (P < 0.01, r = 0.7939, n = 10). (h) The correlation between the levels of LGR5 and CD44 by Spearman correlation analysis (P < 0.01, r = 0.8182, n = 10). (i) Double-staining of LGR5 and N-cadherin in 8591 subcutaneous xenografts. The xenografts edge (section “3 and 4”) showed many positive cells expressed both LGR5 and N-cadherin, while there was few positive cells in inside xenografts (section “Methods”). Scale bar = 100 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (PPTX 6203 kb)